Home
Test for alterations
The VISION trial
Efficacy
Safety, QoL and Dosing

Choose TEPMETKO for lasting efficacy first-line and beyond, confirmed with >18 months' follow-up*1–3

Overview of results
TEPMETKO vs. capmatinib
Tissue biopsy
Liquid biopsy
TEPMETKO vs. other treatments
Intracranial disease control

Overview of results in the VISION trial

In 111 patients with METex14 skipping NSCLC detected by tissue biopsy, first-line TEPMETKO achieved:**1

ORR

58.6%

95% CI: 48.8–67.8

mDOR

46.4

MONTHS

95% CI: 15.2–NE

mPFS

15.9

Months

95% CI: 11.0–49.7

mOS

29.7

months

95% CI: 18.8–NE

TEPMETKO vs. capmatinib

TEPMETKO may offer significantly increased mDOR vs. capmatinib2

A matching-adjusted indirect comparison (MAIC) of TEPMETKO vs. capmatinib has shown improved mDOR, mOS and mPFS2

TEPMETKO vs. capmatinib efficacy outcomes in treatment-naïve patients:

mDOR

mOS

mPFS

TEPMETKO

(ESS=83.3)

46.4

MONTHS

95% CI: 46.4–NE

29.7

MONTHS

95% CI: 14.2–NE

22.0

MONTHS

95% CI: 11.3–NE

Capmatinib

(n=28)

12.6

MONTHS

95% CI: 5.6–NE

20.7

MONTHS

95% CI: 12.5–NE

12.3

MONTHS

95% CI: 8.2–NE

The same trend was observed in previously treated patients2

VISION trial: efficacy in the tissue biopsy subgroup

Tissue biopsy; ‘gold standard’ biopsy method4,5

In 111 patients with METex14 skipping NSCLC detected by tissue biopsy, first-line TEPMETKO achieved:

ORR1

58.6%

95% CI: 48.8–67.8

mDOR1

46.4

MONTHS

95% CI: 15.2–NE

mPFS1

15.9

Months

95% CI: 11.0–49.7

mOS1

29.7

months

95% CI: 18.8–NE

As in the first line, TEPMETKO achieved robust efficacy in previously treated patients which was confirmed with 18 months' follow-up:

ORR1

49.5%

95% CI: 39.2–59.8

mDOR1

12.4

MONTHS

95% CI: 8.3–18.0

mPFS1

11.5

Months

95% CI: 8.2–14.7

mOS1

20.4

MONTHS

95% CI: 17.0–25.5

VISION trial: efficacy in the liquid biopsy subgroup

Liquid biopsy; typically higher tumor burden5,6

In the VISION trial, efficacy over time differed between biopsy subgroups, in line with the liquid biopsy subgroup having a worse prognosis due to a higher tumor burden5,6

TEPMETKO gave patients access to prognosis-transforming targeted therapy via non-invasive (blood draw) detection of alternation1,4

Treatment-naïve patients

ORR1

58.9%

95% CI: 48.4–68.9

mDOR1

19.4

MONTHS

95% CI: 8.3–NE

mPFS1

10.3

MONTHS

95% CI: 8.0–16.5

mOS1

17.6

MONTHS

95% CI: 10.4–23.7

Previously treated patients

ORR1

43.4%

95% CI: 32.5–54.7

mDOR1

12.4

MONTHS

95% CI: 8.4–33.6

mPFS1

8.2

MONTHS

95% CI: 5.7–11

mOS1

16.2

MONTHS

95% CI: 12.0–21.0

With TEPMETKO, help give your patients more moments that matter

TEPMETKO vs. other treatments

Early use of targeted TEPMETKO therapy unlocked lasting efficacy7,8

In treatment-naïve patients, a matched indirect treatment comparison† 
of TEPMETKO vs. real-world outcomes on (chemo-)immunotherapy has confirmed the OS and PFS benefit of using TEPMETKO first-line8

Choose TEPMETKO early to target aggressive METex14 skipping NSCLC7,9

TEPMETKO

29.7

MONTHS’ mOS

(HR 0.64; p=0.05)

vs.

IO monotherapy

18.9

MONTHS’ mOS

TEPMETKO delivered meaningful long-term clinical efficacy in the VISION study, exceeding that seen with standard treatment in prior line†7

Choose TEPMETKO early for your hard-to-treat patients with METex14 skipping NSCLC7,9

TEPMETKO

12.6

MONTHS’ mDOR

Second-line or later

vs.

Prior regimen

6.0

MONTHS’ mDOR

Platinum-based CT, IO monotherapy, or IO + platinum-based CT

Intracranial disease control

Even in patients with METex14 skipping NSCLC and brain metastases, TEPMETKO demonstrated robust intracranial outcomes1

Results reinforced by a substantial and meaningful subgroup of almost 60 patients††1

  • 77% intracranial disease control (n=44/57)10
  • 67% intracranial response (n=10/15)‡10
  • 8.5 months’ (95% CI: 6.8–19.4) intracranial mPFS (n=57)10

Supported by 25% blood-brain barrier penetration in preclinical studies11

BASELINE

1 brain lesion
11.1 mm

WEEK 6

Brain lesion PR 
5.8 mm (-47.8%)

WEEK 36

Brain lesion CR 
0 mm (-100%)

Consider TEPMETKO as a treatment option for your patients 
with METex14 skipping NSCLC and concurrent brain metastases12

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping9,13,14

Explore the importance of timely targeted therapy for your NSCLC patients

Learn more about the unmet need

Explore the VISION trial

Learn more about the patient characteristics, efficacy outcomes and design of VISION, a single-arm, open-label, multicenter, non-randomized, multi-cohort study that analyzed patients with METex14 skipping NSCLC (N=313)1,13

Learn more about the VISION trial

TEPMETKO demonstrated a manageable safety profile that maintained QoL**1,10,15–17

Most common AEs were mild to moderate10

Learn more about safety, dosing and QoL

*Cohort A follow-up >35 months; Cohort C follow-up >18 months; median follow-up of Cohorts A+C 32.6 months1
**Data shown are from Cohorts A+C1
†This is not a direct head-to-head comparison study
††All lines combined; tissue and liquid biopsy10
‡Excludes non-target brain lesions10

Abbreviations

AE, adverse event; CI, confidence interval; CR, complete response; CT, chemotherapy; ESS, effective sample size; HR, hazard ratio; IO, immunotherapy; MAIC, matching-adjusted indirect comparison; mDOR, median duration of reponse; METex14, mesenchymal epithelial transition factor exon 14; mOS median overall survival; mPFS, median progression-free survival; MRI, magnetic resonance imaging; NSCLC; non-small cell lung cancer; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; QoL, quality of life

References
  1. Mazieres J et al. JAMA Oncol  2023; 9:1260−1266.
  2. Pfeiffer BM et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2023; 9−12 September 2023; Virtually and Singapore (Poster no. 1312).
  3. TEPMETKO® (tepotinib) [prescribing information], EMD Serono, Inc., Rockland, MA; 2024.
  4. Di Capua D et al. Cancers  2021; 13:3923..
  5. Rolfo C et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1382P)..
  6. Le X et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2023; 9−12 September 2023; Singapore (Presentation no. OA21.06).
  7. Viteri S et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1380P).
  8. Christopoulos P et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1381P).
  9. Tong JH et al. Clin Cancer Res  2016; 22:3048–3056.
  10. Mazieres J et al. JAMA Oncol  2023; 9:1260–1266 (supplementary appendix 2).
  11. Thomas M et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2022; 6–9 August 2022; Vienna, Austria (Presentation no. OA03.05).
  12. Le X et al. Clin Cancer Res  2022; 28:1117–1126.
  13. Paik PK et al. N Engl J Med  2020; 383:931–943.
  14. Salgia R. Mol Cancer Ther  2017; 16:555–565.
  15. Paik PK et al. Presented virtually at: American Society of Clinical Oncology (ASCO) Annual Meeting 2023; 2–6 June 2023; Chicago, IL, USA (Abstract no. 9060).
  16. Veillon R et al. Clin Lung Cancer  2022; 23:320–332.
  17. Ahn L et al. Clin J Oncol Nurs  2022; 26:543–551.

This website is an international information resource intended only for healthcare professionals from outside the European Economic Area (EEA), the US, Puerto Rico and Canada who are interested in information on TEPMETKO. The information on this website contains educational and promotional material. By clicking on 'I'm a healthcare professional' you are declaring and confirming that are you a healthcare professional and have read and understood this.

I’m a healthcare professional

I’m not a healthcare professional

GL-TEP-00506 | April 2025

© 2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. TEPMETKO is a registered trademark of Merck KGaA, Darmstadt, Germany.

This website is an international information resource intended only for Healthcare Professionals from outside the European Economic Area (EEA), the US, Puerto Rico
and Canada who are interested in information on TEPMETKO.

Terms and Conditions     Privacy Policy    Legal Statement   Site Map    Contact Us

Terms and Conditions    Privacy Policy     Legal Statement    Site Map    Contact Us

Cookie Disclamer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy.

GOT IT!
COOKIE SETTINGS

These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.

 

These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.

In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.